Coave Therapeutics
A clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD241—361m (Dealroom.co estimates Jul 2021.)
Company register number 800830721
Paris Île-de-France (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 |
---|---|---|---|
Profit | (<1m) | 1.6m | 3.3m |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Support Program | ||
N/A | Spinout | ||
€450k | Seed | ||
* | €4.0m | Series A | |
€19.0m | Series B | ||
€22.5m | Series B | ||
* | $38.9m | Series B | |
* | N/A | Grant | |
Total Funding | AUD138m |
Recent News about Coave Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.